Co‐reactivation of the human herpesvirus alpha subfamily (herpes simplex virus‐1 and varicella zoster virus) in a critically ill patient with COVID‐19

Xu, Runda; Zhou, Yu Jie; Cai, Lihua; Wang, L.; Han, Jian; Yang, Xiaoyun; Chen, J.; Ma, Charlie; Shen, Lihan

doi:10.1111/bjd.19484

Cited by 85 publications

(92 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a few situations, the diagnosis was based on telemedicine consultations and photographs/videos [ 6 , 7 , 13 ]. Supportive laboratory testing for HZ was available in a limited number of cases [ 10 , 12 , 15 ].…”

Section: Resultsmentioning

confidence: 99%

“…Demographic and Co-Morbid Conditions Cases included both genders and were reported worldwide, including Europe (Italy, Spain), Asia (Saudi Arabia, China, India), Africa (Egypt), North America (United States) and South America (Brazil) [6][7][8][9][10][11][12][13][14][15][16][17]. There were cases with known risk factors for HZ, which included age[ 50 years (n = 18), immunosuppressive therapies/immunomodulators (n = 2) and diabetes mellitus (n = 3) [5,7,8,10,11,[13][14][15][16][17].…”

Section: Description Of Hz Cases In Patients With Covid-19mentioning

confidence: 99%

See 1 more Smart Citation

Can COVID-19 Increase the Risk of Herpes Zoster? A Narrative Review

Díez-Domingo

Parikh

Bhavsar

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Herpes zoster (HZ) is associated with substantial morbidity. It is caused by reactivation of the latent varicella zoster virus (VZV) following decline in cell-mediated immunity, which is commonly age-related, but also occurs in individuals with immunosuppressive diseases and/ or treatment. Since coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has been associated with T cell immune dysfunction and there have been reports of HZ in COVID-19 patients, we have performed a review of available literature on whether COVID-19 could trigger HZ. We identified 27 cases of HZ following COVID-19, which most frequently occurred within 1-2 weeks of COVID-19, and the majority of cases had typical presentation. Atypical presentations of HZ were noted especially in patients with lymphopenia. It has been hypothesized that VZV reactivation occurs as a consequence of T cell dysfunction (including lymphopenia and lymphocyte exhaustion) in COVID-19 patients. Based on current evidence, which is limited to case reports and case series, it is not possible to determine whether COVID-19 increases the risk of HZ. Practitioners should be aware of the possible increased risk of HZ during the pandemic period and consider timely therapeutic and preventive measures against it.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Description Of Hz Cases In Patients With Covid-19mentioning

confidence: 99%

Can COVID-19 Increase the Risk of Herpes Zoster? A Narrative Review

Díez-Domingo

Parikh

Bhavsar

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…A major strength of our newly developed SARS-CoV-2 serological assay is its multiplex approach, allowing for the assessment of up to 100 antigens in parallel. It does not only permit inclusion of multiple SARS-CoV-2 proteins but also autoantigens or antigens from pathogens that might induce antibody responses due to (re-)activation or co-infection during the course of COVID-19 disease, as it was previously described for Herpesviruses [ 25 , 26 , 27 ]. We furthermore demonstrated the possibility to quantify longitudinally the humoral anti-SARS-CoV-2 responses for different Ig isotypes.…”

Section: Discussionmentioning

confidence: 99%

From Multiplex Serology to Serolomics—A Novel Approach to the Antibody Response against the SARS-CoV-2 Proteome

Butt

Murugan

Hippchen

et al. 2021

Viruses

View full text Add to dashboard Cite

The emerging SARS-CoV-2 pandemic entails an urgent need for specific and sensitive high-throughput serological assays to assess SARS-CoV-2 epidemiology. We, therefore, aimed at developing a fluorescent-bead based SARS-CoV-2 multiplex serology assay for detection of antibody responses to the SARS-CoV-2 proteome. Proteins of the SARS-CoV-2 proteome and protein N of SARS-CoV-1 and common cold Coronaviruses (ccCoVs) were recombinantly expressed in E. coli or HEK293 cells. Assay performance was assessed in a COVID-19 case cohort (n = 48 hospitalized patients from Heidelberg) as well as n = 85 age- and sex-matched pre-pandemic controls from the ESTHER study. Assay validation included comparison with home-made immunofluorescence and commercial enzyme-linked immunosorbent (ELISA) assays. A sensitivity of 100% (95% CI: 86–100%) was achieved in COVID-19 patients 14 days post symptom onset with dual sero-positivity to SARS-CoV-2 N and the receptor-binding domain of the spike protein. The specificity obtained with this algorithm was 100% (95% CI: 96–100%). Antibody responses to ccCoVs N were abundantly high and did not correlate with those to SARS-CoV-2 N. Inclusion of additional SARS-CoV-2 proteins as well as separate assessment of immunoglobulin (Ig) classes M, A, and G allowed for explorative analyses regarding disease progression and course of antibody response. This newly developed SARS-CoV-2 multiplex serology assay achieved high sensitivity and specificity to determine SARS-CoV-2 sero-positivity. Its high throughput ability allows epidemiologic SARS-CoV-2 research in large population-based studies. Inclusion of additional pathogens into the panel as well as separate assessment of Ig isotypes will furthermore allow addressing research questions beyond SARS-CoV-2 sero-prevalence.

show abstract

“…A major strength of our newly developed SARS-CoV-2 serological assay is its multiplex approach, allowing for the assessment of up to 100 antigens in parallel. It does not only permit inclusion of multiple SARS-CoV-2 proteins but also autoantigens or antigens from pathogens that might induce antibody responses due to (re-)activation or co-infection during the course of Covid-19 disease, as it was previously described for Herpesviruses (Amorim Dos Santos et al, 2020; Elsaie et al, 2020; Xu et al, 2020). We furthermore demonstrated the possibility to quantify longitudinally the humoral anti-SARS-CoV-2 responses for different Ig isotypes.…”

Section: Discussionmentioning

confidence: 99%

From multiplex serology to serolomics – a novel approach to the antibody response against the SARS-CoV-2 proteome

Butt

Murugan

Hippchen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The emerging SARS-CoV-2 pandemic entails an urgent need for specific and sensitive high-throughput serological assays to assess SARS-CoV-2 epidemiology. We therefore aimed at developing a fluorescent-bead based SARS-CoV-2 multiplex serology assay for detection of antibody responses to the SARS-CoV-2 proteome. Methods: Proteins of the SARS-CoV-2 proteome and protein N of SARS-CoV-1 and common cold Coronaviruses (ccCoVs) were recombinantly expressed in E. coli or HEK293 cells. Assay performance was assessed in a Covid-19 case cohort (n=48 hospitalized patients from Heidelberg) as well as n=85 age- and sex-matched pre-pandemic controls from the ESTHER study. Assay validation included comparison with home-made immunofluorescence and commercial Enzyme-linked immunosorbent (ELISA) assays. Results: A sensitivity of 100% (95% CI: 86%-100%) was achieved in Covid-19 patients 14 days post symptom onset with dual sero-positivity to SARS-CoV-2 N and the receptor-binding domain of the spike protein. The specificity obtained with this algorithm was 100% (95% CI: 96%-100%). Antibody responses to ccCoVs N were abundantly high and did not correlate with those to SARS-CoV-2 N. Inclusion of additional SARS-CoV-2 proteins as well as separate assessment of immunoglobulin (Ig) classes M, A, and G allowed for explorative analyses regarding disease progression and course of antibody response. Conclusion: This newly developed SARS-CoV-2 multiplex serology assay achieved high sensitivity and specificity to determine SARS-CoV-2 sero-positivity. Its high throughput ability allows epidemiologic SARS-CoV-2 research in large population-based studies. Inclusion of additional pathogens into the panel as well as separate assessment of Ig isotypes will furthermore allow addressing research questions beyond SARS-CoV-2 sero-prevalence.

show abstract

Co‐reactivation of the human herpesvirus alpha subfamily (herpes simplex virus‐1 and varicella zoster virus) in a critically ill patient with COVID‐19

Cited by 85 publications

References 8 publications

Can COVID-19 Increase the Risk of Herpes Zoster? A Narrative Review

Can COVID-19 Increase the Risk of Herpes Zoster? A Narrative Review

From Multiplex Serology to Serolomics—A Novel Approach to the Antibody Response against the SARS-CoV-2 Proteome

From multiplex serology to serolomics – a novel approach to the antibody response against the SARS-CoV-2 proteome

Contact Info

Product

Resources

About